Skip to the page

Data / Drug companies / Bamboo US Bidco LCC

Bamboo US Bidco LCC: 33 products in the FDA NDC directory, labeler code 83703

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Bamboo US Bidco LCC (labeler code 83703) lists 33 products in the FDA National Drug Code Directory, covering 4 finished drugs by generic name. By type: 24 drugs for further processing, 5 vaccines. Its main marketing category is drugs for further processing. The newest product started marketing on October 8, 2026.

The request: Watch Bamboo US Bidco LCC (FDA labeler code 83703): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
83703
Products in commercial distribution
33
Packages
34
Finished drugs by generic name
4
Prescription products
4
Over the counter products
0
Flagged as original packager
4 of 4 products that carry the flag
Started marketing in the last 12 months
5
Earliest marketing start
October 20, 1976
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing2472.7%
Biologics (BLA)515.2%
Generic drugs (ANDA)39.1%
New drug applications (NDA)13%

Products by type

TypeProductsShare
Drugs for further processing2472.7%
Vaccines515.2%
Prescription drugs412.1%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution824.2%
Injection, powder, lyophilized, for solution824.2%
Injection, powder, for solution515.2%
Injection, suspension412.1%
Injection412.1%
Injection, solution, concentrate26.1%
Injection, powder, lyophilized, for suspension13%
Powder, for solution13%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Temolozomide83703-608Injection, powder, lyophilized, for solutionDrugs for further processingOctober 8, 2026
Flucelvax83703-088Injection, suspensionBiologics (BLA)August 1, 2026
Fluzone trivalent northern hemisphere83703-087Injection, suspensionBiologics (BLA)July 1, 2026
Recombivax hb83703-086Injection, suspensionBiologics (BLA)February 26, 2026
Recombivax hb83703-085Injection, suspensionBiologics (BLA)February 26, 2026
Zolbetuximab83703-511InjectionDrugs for further processingFebruary 21, 2025
Datopotamab deruxtecan83703-530InjectionDrugs for further processingApril 12, 2024
Zolbetuximab83703-516InjectionDrugs for further processingFebruary 29, 2024
Mecasermin83703-569Injection, solutionDrugs for further processingJanuary 31, 2022
Mecasermin83703-568Injection, solutionDrugs for further processingJanuary 31, 2022
Tisotumab vedotin83703-579Injection, powder, for solutionDrugs for further processingSeptember 20, 2021
Tisotumab vedotin83703-578Injection, powder, for solutionDrugs for further processingSeptember 20, 2021
Rituximab-arrx83703-576Injection, solutionDrugs for further processingDecember 19, 2020
Rituximab-arrx83703-575Injection, solutionDrugs for further processingDecember 19, 2020
Rituximab-arrx83703-574Injection, solutionDrugs for further processingDecember 19, 2020
Rituximab-arrx83703-573Injection, solutionDrugs for further processingDecember 19, 2020
Rituximab-abbs83703-582Injection, solution, concentrateDrugs for further processingDecember 1, 2020
Rituximab-abbs83703-581Injection, solution, concentrateDrugs for further processingOctober 1, 2020
Lurbinectedin83703-583Injection, powder, lyophilized, for solutionDrugs for further processingJune 15, 2020
Enfortumab vedotin83703-571Injection, powder, lyophilized, for solutionDrugs for further processingDecember 18, 2019
Enfortumab vedotin83703-570Injection, powder, lyophilized, for solutionDrugs for further processingDecember 18, 2019
Trastuzumab deruxtecan83703-580Injection, powder, lyophilized, for solutionDrugs for further processingMay 22, 2019
Heplisav-b83703-048Injection, solutionBiologics (BLA)January 1, 2018
Brentuximab vedotin83703-564Powder, for solutionDrugs for further processingAugust 25, 2011
Temozolomide83703-577Injection, powder, lyophilized, for solutionDrugs for further processingFebruary 27, 2009

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.